Eli Lilly and Company (LLY)
| Market Cap | 692.75B |
| Revenue (ttm) | 34.12B |
| Net Income (ttm) | 5.24B |
| Shares Out | 950.77M |
| EPS (ttm) | 5.80 |
| PE Ratio | 126.37 |
| Forward PE | 58.29 |
| Dividend | $5.20 (0.71%) |
| Ex-Dividend Date | Feb 14, 2024 |
| Volume | 1,649,745 |
| Open | 749.16 |
| Previous Close | 745.95 |
| Day's Range | 725.47 - 750.01 |
| 52-Week Range | 370.68 - 800.78 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 714.14 (-1.99%) |
| Earnings Date | Apr 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $714.14, which is a decrease of -1.99% from the latest price.
News
Eli Lilly's Chart Gets Another Boost from Obesity Drug
From diabetes to heart disease, the obesity drug Zepbound has been shown to have positive effects for other health ailments. Now, the company has a trial pointing to reduced sleep apnea severity.
Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea
Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its weight-loss drug, Zepbound, was effective in treating those who are overw...
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Eli Lilly's weight-loss drug Zepbound might help cure your sleep apnea
Eli Lilly and Company announced promising results for its weight loss drug Zepbound, indicating its potential as a treatment for sleep apnea. The drug demonstrated effectiveness in reducing the severi...
Weight Loss Drug Zepbound May Reduce Sleep Apnea, Eli Lilly Says
A late-stage trial of Eli Lilly's weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings suggesting p...
Cramer's Mad Dash: Eli Lilly
CNBC's Jim Cramer delivers his daily Mad Dash.
Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarte...
It's Not Just Weight Loss. Eli Lilly Obesity Drug Works on This Chronic Condition.
Lilly's weight loss drug significantly reduced the severity of sleep apnea in obese adults in clinical trials.
Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients
Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday.
Eli Lilly reports positive data in Phase 3 trial of weight-loss drug as treatment for sleep apnea
Eli Lilly & Co. LLY, -0.54% said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced sleep apnea...
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trials
The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials Tirzepatide mea...
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
INDIANAPOLIS , April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that...
No Evidence Linking Ozempic And Suicidal Thoughts, EU Says
There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting do...
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts s...
Popular weight-loss drug doesn't increase suicide risk, EU regulator says
A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board
STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS...
Cramer says stocks that pulled back Tuesday still 'have everything going for them'
CNBC's Jim Cramer reviewed Tuesday's market action, saying stocks that saw losses like Nvidia and Eli Lilly remain winners.
Wegovy's heart benefits are not just linked with weight loss, new study suggests
People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, accord...
Outperforming ETF manager names a potential ‘50-bagger' in the stock market
The Simplify Health Care exchange-traded fund has grown to $136 million in assets in two and a half years. It is never easy for an actively managed fund to outperform its benchmark or a broad stock-ma...
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne...
Top three US healthcare stocks to buy in April
As we look forward to celebrating World Health Day on April 7th, these are the top three healthcare US companies we think you should be watching for your financial health. 1. Lilly (Eli) & Co.